Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Income from Continuing Operations (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Income from Continuing Operations data on record, last reported at 111578000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 402.03% year-over-year to 111578000.0; the TTM value through Dec 2025 reached 158000.0, up 99.95%, while the annual FY2025 figure was 158000.0, 99.95% up from the prior year.
  • Income from Continuing Operations reached 111578000.0 in Q4 2025 per AMLX's latest filing, up from 34386000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 111578000.0 in Q4 2025 and bottomed at 118793000.0 in Q1 2024.
  • Average Income from Continuing Operations over 5 years is 27083800.0, with a median of 35146500.0 recorded in 2025.
  • Peak YoY movement for Income from Continuing Operations: crashed 7652.0% in 2024, then soared 402.03% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 28344000.0 in 2021, then tumbled by 54.55% to 43807000.0 in 2022, then skyrocketed by 105.65% to 2473000.0 in 2023, then crashed by 1593.85% to 36943000.0 in 2024, then skyrocketed by 402.03% to 111578000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 111578000.0 in Q4 2025, 34386000.0 in Q3 2025, and 41443000.0 in Q2 2025.